Bayer shares eked out a 1.58% gain on Friday to close at €35.95, nudging just above their 200-day moving average of €35.80. But the technical foothold masks a deepening sense of unease across the German pharma landscape, where investment decisions and a CEO’s blunt assessment of the home market are casting long shadows.
Two of Bayer’s competitors have slammed the brakes on domestic capital expenditure. Boehringer Ingelheim shelved plans worth €900 million, while Eli Lilly halved its ambitions for a new production facility, cutting the bulk of the 1,000 originally envisioned jobs. Both companies cited the government’s health spending squeeze as the culprit — a dynamic that also pressures Bayer’s own pharmaceutical margins. For a group that ranks among Germany’s largest drugmakers, the signal is unmistakable: planning security is eroding just when the sector needs it most.
That sentiment was echoed by Bayer CEO Bill Anderson in a rare, wide-ranging interview published on June 5. He took direct aim at Germany’s cost base, noting that electricity prices are more than triple those on the Texas Gulf Coast and more than double those in China. High ancillary wage costs and a growing thicket of bureaucracy, he argued, are choking innovation rather than fostering it. He called on Chancellor Merz to set a clearer mission for new inventiveness, warning that the structural disadvantages will persist regardless of the geopolitical outlook.
Beyond domestic headwinds, Anderson flagged a geopolitical risk with direct consequences for Bayer’s core agricultural business. Roughly a third of global nitrogen fertilizer trade passes through the Strait of Hormuz, and a prolonged blockade could slash Northern Hemisphere harvests as early as autumn. Fewer crops mean less purchasing power for farmers — and that translates directly into lower demand for seeds, the lifeblood of Bayer’s Crop Science division. That unit grew 6.8% to €7.558 billion in the first quarter of 2026, but Anderson warned that some of that momentum was not built to last.
Should investors sell immediately? Or is it worth buying Bayer?
Legal overhangs also remain thick on the ground. A new class action alleging monopolistic practices in genetically modified corn seed has hit the headlines, and the long-running $7.25 billion Roundup settlement continues to cast a shadow. Yet analysts at mwb Research see operational improvements in both Crop Science and pharma as outweighing litigation risk. They reiterated a “Buy” rating with a €52 target, implying roughly 45% upside from current levels — and described neither legal case as a decisive obstacle to the share price.
The near-term catalyst, however, could come from the US Supreme Court. According to JPMorgan, a ruling on the glyphosate cases is expected toward the end of June, with a first “opinion day” already announced for June 11. Approximately 80% of the still-pending suits against Bayer would be affected by the decision — a trigger far more powerful than any political debate over Germany’s location.
Technically, the stock remains in a precarious position. It sits below both its 50-day (€38.39) and 100-day (€40.50) averages, with the 200-day line at €35.80 acting as the only firm support. The RSI at 42.6 signals no extremes, while volatility hovers near 37%. Whether that support holds may depend on whether policymakers in Berlin respond to the pharmaceutical investment chill with more than words. For now, the line is drawn at €35.80 — and if it breaks, the technical picture turns sharply darker.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from June 7 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 7.
Bayer: Buy or sell? Read more here...
